argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of argenex SE (NASDAQ:ARGX - Get Free Report) have earned a consensus rating of "Buy" from the twenty-two analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $709.18.

Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded argenex from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Citigroup restated a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. Wedbush reiterated an "outperform" rating and set a $715.00 price target on shares of argenex in a research note on Wednesday, June 11th. JMP Securities set a $699.00 price objective on argenex in a report on Wednesday, May 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of argenex in a report on Friday, February 28th.

argenex Price Performance

Shares of NASDAQ ARGX traded down $2.79 during mid-day trading on Monday, reaching $537.92. 252,942 shares of the company's stock were exchanged, compared to its average volume of 326,238. The firm has a 50-day moving average price of $586.57 and a two-hundred day moving average price of $610.16. The firm has a market capitalization of $32.85 billion, a price-to-earnings ratio of 33.18, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39. argenex has a 52 week low of $379.39 and a 52 week high of $678.21.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. As a group, sell-side analysts forecast that argenex will post 3.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ARGX. Point72 Europe London LLP bought a new stake in argenex during the fourth quarter valued at $5,839,000. Stephens Inc. AR bought a new stake in shares of argenex during the 4th quarter valued at about $310,000. Ameriprise Financial Inc. boosted its position in shares of argenex by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock valued at $4,313,000 after acquiring an additional 639 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of argenex by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of argenex by 13.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,538 shares of the company's stock worth $946,000 after purchasing an additional 181 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.